Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development
NCT ID: NCT03775902
Last Updated: 2023-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2018-12-19
2020-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of K+ and Ca2+ in Development of Muscle Fatigue
NCT02712658
Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness
NCT00745771
Autonomic Nervous System and Chronic Fatigue Syndrome
NCT00580619
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
NCT00977171
Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa
NCT01149629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy subjects
Two experimental day where the effect of Nicorandil (20mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
Placebo
placebo tablet
Nicorandil
20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
Insulin resistant
Two experimental day where the effect of Nicorandil (20mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
Placebo
placebo tablet
Nicorandil
20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
placebo tablet
Nicorandil
20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c \<38 mmol/mol (\<5.7%), HOMA-IR \> 1.7 (insulin resistant)
* VO2max \<40 ml/kg/min (insulin resistant), 45-55 ml/kg/m2 (healthy)
* BMI \>26 kg/m2 (insulin resistant), 19-26 kg/m2 (healthy)
Exclusion Criteria
* Allergy towards Nicorandil
* Chronic disease other than type 2 diabetes deemed to interfere with study outcomes
* Excessive alcohol consumption (\>14 units/week)
* Abnormal ECG
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Copenhagen
Copenhagen, Danmark, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAK-KATP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.